Amylyx prices $471.7M equity offering to fund avexitide launch

Amylyx Pharmaceuticals, Inc.

14,090,000 shares at $35.50/share; 30-day option for 2,113,500 more.
Net proceeds ~$471.7M (~$542.5M if option fully exercised).
Proceeds to fund potential U.S. launch of avexitide, R&D, working capital.
Offering expected to close Aug 21, 2026; underwriters: Leerink, Morgan Stanley, Guggenheim, LifeSci.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.